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Abstract. The endogenous cannabinoid system represents a promising therapeutic target to modify neurodegenerative path-
ways linked to Alzheimer’s disease (AD). The aim of the present study was to evaluate the specific contribution of CB2
receptor to the progression of AD-like pathology and its role in the positive effect of a cannabis-based medicine (1:1 com-
bination of 9-tetrahidrocannabinol and cannabidiol) previously demonstrated to be beneficial in the APP/PS1 transgenic
model of the disease. A new mouse strain was generated by crossing APP/PS1 transgenic mice with CB2 knockout mice.
Results show that lack of CB2 exacerbates cortical A deposition and increases the levels of soluble A40. However, CB2
receptor deficiency does not affect the viability of APP/PS1 mice, does not accelerate their memory impairment, does
not modify tau hyperphosphorylation in dystrophic neurites associated to A plaques, and does not attenuate the positive
cognitive effect induced by the cannabis-based medicine in these animals. These findings suggest a minor role for the CB2
receptor in the therapeutic effect of the cannabis-based medicine in APP/PS1 mice, but also constitute evidence of a link
between CB2 receptor and A processing.
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INTRODUCTION
CB2 receptors are one of the main components of
the endogenous cannabinoid system, a lipid signal-
ing network involved in the maintenance of cellular
homeostasis in the central nervous system and other
peripheral tissues. These Gi/o-coupled receptors are
mainly located in immune system cells including
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microglia. The stimulation of CB2 receptors by
endogenous or exogenous cannabinoid compounds
modulates an array of signaling pathways that in the
end lead to immune cell migration and control of
cytokine release [1]. Thus, CB2 receptors are impli-
cated in the reduction of pro-inflammatory molecules
in response to harmful stimuli [2]. However, rela-
tively low CB2 receptor expression is also observed in
brain neurons under certain conditions [3–6]. More-
over, recent findings reveal that CB2 receptors are
involved in several physiological processes related to
neuronal activity [4, 5, 7, 8].
Alzheimer’s disease (AD), the most frequent
neurodegenerative disease, is characterized by the
presence of amyloid- (A) deposition and neuronal
tau hyperphosphorylation in brain, accompanied by
energetic failure, oxidative stress, and neuroinflam-
mation [9, 10]. Previous studies have shown the
participation of CB2 receptors in AD. CB2 receptor
levels are increased in postmortem brains, specifi-
cally in astrocytes and predominantly in microglia
surrounding A plaques [11–14]. Pharmacological
stimulation of these receptors facilitates A removal
[15–17], reduces neuroinflammation [12, 16–21], and
facilitates cognitive improvement [16, 17, 21] in dif-
ferent animal models of the disease. Moreover, CB2
receptors modulate oxidative stress damage and tau
hyperphosphorylation in AD models [21, 22]. How-
ever, the pathophysiological role of CB2 receptors in
the progression of the disease remains to be eluci-
dated.
A recent report has shown that administration of a
combination of two botanical extracts derived from
the plant Cannabis sativa, one of them enriched in
9-tetrahydrocannabinol (9-THC) and the other in
cannabidiol (CBD), results in cognitive improvement
together with reduction of several pathologic parame-
ters in APP/PS1 transgenic mice, a well-established
murine model of AD-related pathology [23]. In the
same line, positive effects of the combination of 9-
THC and CBD botanical drug substances (BDS) have
been reported on the altered behavior in a murine
model of tauopathy [24]. Moreover, some previous
findings demonstrated a beneficial effect of 9-THC
[25] and CBD [26–28] separately in other AD mod-
els. The mechanism of action of such compounds is
still not fully understood. 9-THC and CBD act on
different signaling pathways [29, 30], and the fact that
their combination produces better therapeutic effects
than that resulting from treatment with only one of the
components suggests a cumulative effect or a positive
interaction between the two compounds. Moreover,
it is important to notice that other phytocannabi-
noids and terpens, including tetrahydrocannabivarin,
cannabigerol, cannabichromene among others, which
were initially considered inactive compounds but that
have recently demonstrated to exert per se addi-
tional therapeutic effects, are also present in minor
proportions in these botanical extracts. A synergy
between the main components (9-THC and CBD)
and such other phytocannabinoids might also occur
when using cannabis botanical extracts, resulting in
a potentiation or inhibition of their activity, in a
summation of effects and/or in pharmacokinetic and
metabolic interactions [31].
The aim of the present study was to evaluate the
specific contribution of CB2 receptor to the progres-
sion of the AD-like pathology and its role in the
positive effect of the 1:1 combination of 9-THC
BDS and CBD BDS in APP/PS1 transgenic mice.
MATERIALS AND METHODS
Animals
A new mouse strain was generated by crossing
male APP/PS1 mice (APPswe and PS1dE9) [32]
purchased from Jackson Laboratories (Bar Harbor,
Maine, USA) with female CB2 knockout (KO) mice
[33] obtained from the European Mutant Mouse
Archive (Helmholtz Zentrum, München, Germany),
both strains in a C57BL/6 background. The result-
ing APP/PS1/CB2 heterozygous (HET) males were
then crossed with wild-type (WT)/CB2 HET females
to obtain the animals for the present study. The geno-
type of the pups was evaluated with the polymerase
chain reaction (PCR) technique using genomic DNA
isolated from tail clips. CB2 HET mice were ruled
out for the subsequent experiments. Memory per-
formance was evaluated in WT/CB2 WT, WT/CB2
KO, APP/PS1/CB2 WT, and APP/PS1/CB2 KO
male littermates aged 3 and 6 months. The phar-
macological study was carried out in males aged
6 months (early symptomatic phase in APP/PS1
mice). Animals were maintained under standard ani-
mal housing conditions in a 12-h dark-light cycle with
free access to food and water. Mice were randomly
assigned to treatment groups and the experiments
were conducted under blind experimental conditions.
All animal procedures were carried out following
the guidelines of the European Communities Coun-
cil Directive 2010/63/EU and with the approval of
the local ethical committees of the University of
Barcelona and University Pompeu Fabra.
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Pharmacological treatment
9-THC BDS (containing 67.1% 9-THC, 0.3%
CBD, 0.9% cannabigerol, 0.9% cannabichromene,
and 1.9% other phytocannabinoids) and CBD BDS
(containing 64.8% CBD, 2.3% 9-THC, 1.1%
cannabigerol, 3.0% cannabichromene, and 1.5%
other phytocannabinoids) were supplied by GW
Pharmaceuticals Ltd (Cambridge, UK). The 1:1 mix-
ture of both extracts (9-THC BDS 0.75 mg/kg
+ CBD BDS 0.75 mg/kg) was dissolved in 5%
ethanol, 5% Tween, and 90% saline, and injected
intra-peritoneally (i.p.) in a volume of 10 mL/kg
body weight. The selection of the dose was
based on previous studies revealing a therapeutic
effect of the 9-THC +CBD BDS combination in
APP/PS1 mice [34]. Animals were treated once
a day for 5 weeks with the extracts (WT/CB2WT,
n = 7; APP/PS1/CB2WT, n = 6; WT/CB2 KO, n = 8;
APP/PS1/CB2 KO, n = 8) or the corresponding
vehicle (WT/CB2WT, n = 8; APP/PS1/CB2WT,
n = 5; WT/CB2 KO, n = 7; APP/PS1/CB2 KO,
n = 8). After a 4-day washing period, animals were
subjected to behavioral evaluation.
Behavioral evaluation of cognitive performance
Two-object recognition test
On day 1, mice were habituated for 9 min to a
V-maze allowing them to freely explore the appa-
ratus. On the second day, mice were placed for 9 min
in the maze where two identical objects were sit-
uated at the end of the arms; the time that mice
spent exploring each object was recorded. Twenty-
four hours after the training session, animals were
placed again in the V-maze where one of the two
familiar objects was replaced by a novel object. The
time that the animals spent exploring the two objects
was recorded. Object recognition index (RI) was
calculated as the difference between the time spent
exploring the novel (TN) and the familiar object (TF)
divided by the total time spent exploring the two
objects [RI = (TN–TF)/(TN+TF)]. Animals exhibiting
memory impairments showed a lower RI.
Active avoidance test
After the two-object recognition test, the animals
were allowed to rest for 7 days before starting the
active avoidance test. Mice were trained to avoid an
aversive stimulus associated with the presentation of
a conditioned stimulus (CS) in a two-way shuttle box
apparatus (Panlab, Barcelona, Spain). The CS was
a light (10 W) switched on in the compartment in
which the mouse was placed. The CS was received
5 s before the onset of the unconditioned stimulus
(US) and overlapped it for 25 s. At the end of the 30-
s period, both CS and US were automatically turned
off. The US was an electric shock (0.2 mA) continu-
ously applied to the grid of the floor. A conditioned
response was recorded when the animal avoided the
US by changing from the compartment where it
received the CS to the opposite compartment within
the 5 s period after the onset of the CS. If animals
failed to avoid the shock, they could escape it by
crossing during the US (25 s), and this was recorded
as unconditioned response. Between each trial ses-
sion, there was an inter-trial interval of 30 s. Animals
were subjected to five daily 100-trial active avoidance
sessions. Each day, mice were placed in the shuttle
box for 10 min before the start of each session to allow
them to explore the box.
At the end of the behavioral testing, the animals
were sacrificed by cervical dislocation, and their
brains were rapidly removed from the skulls and pro-
cessed for study. One hemisphere was dissected on
ice, immediately frozen, and stored at –80ºC until use.
The other hemisphere was fixed in 4% paraformalde-
hyde and processed for immunohistochemistry.
Aβ immunohistochemistry
Fixed tissue samples were embedded in paraf-
fin, and coronal sections, 4 m thick, were cut with
a microtome. Consecutive de-waxed sections were
incubated with 98% formic acid (3 min) and then
treated with citrate buffer (20 min) to enhance anti-
genicity. Then endogenous peroxidases were blocked
by incubation in 10% methanol-1% H2O2 solution
(15 min). Sections were blocked with 3% normal
horse serum solution and then incubated at 4◦C
overnight with the primary antibody against total A
(clone 6F/3D 1:50, Dako, Glostrup, Denmark), A40
(1:100, Merck Millipore, Billerica, MA, USA), or
A42 (1:50, Merck Millipore). Sections were sub-
sequently rinsed and incubated with biotinylated
secondary antibody (Dako). Peroxidase reaction was
visualized with diaminobenzidine and H2O2. Sec-
tions were lightly counterstained with hematoxylin.
After staining, the sections were dehydrated and
cover-slipped for observation under a Nikon Eclipse
E800 microscope (Nikon Imaging Inc., Tokyo,
Japan). The cortical total A burden was calculated
as the percentage of the area of amyloid deposition
in plaques with respect to the total cortical area (0.6
mm2) in 9 pictures taken from 3 different sections
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(–0.1 mm, –1.5 mm, and –2.0 mm from bregma) of
the each animal brain (3 pictures per section corre-
sponding to cingular/retrospenial and motor cortex,
somatosensory cortex, and piriform/entorrhinal cor-
tex), corresponding to the main regions where A
deposition is observed in APP/PS1 mice [23, 24].
Two sections of the hippocampus of each animal
(–1.5 mm and –2.0 mm from bregma) were used for
quantification of the hippocampal A burden, calcu-
lated as the percentage of the amyloid deposition in
plaques with respect to the total hippocampal area in
each section. The ratio between A42 and A40 depo-
sition in each plaque was calculated by comparing
the specific staining with each antibody in at least 15
cortical plaques per animal in consecutive sections.
Quantifications were performed by a researcher blind
for the corresponding genotype or treatment of each
section. A quantification was calculated using the
Analysis tool of the Adobe® Photoshop® CS4 soft-
ware (Adobe Systems Inc., San Jose, CA, USA). All
the APP/PS1-treated animals were analyzed.
Aβ soluble quantification: Enzyme-linked
immunosorbent assay (ELISA)
Fresh-frozen mouse brain cortex was homoge-
nized in 4 volumes (wt:vol) of TBS extraction
buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH
7.4), 5 mM EDTA, and protease inhibitor cocktail
(Roche Molecular Systems, Pleasanton, CA, USA).
Homogenate was spun 100,000 g × 1 h, and the
supernatant was saved as the soluble fraction for A
quantification. A40 and A42 Human ELISA kits
(InvitrogenTM Corporation, Camarillo, CA, USA)
were used to quantify the levels of A40 and A42
peptides in the brain soluble fractions. Quantita-
tive determination was carried out according to the
manufacturer’s instructions. A40 and A42 lev-
els were normalized to the total amount of protein
from each individual sample (BCA method, Thermo
Fisher Scientific, Wilmington, DE, USA). All the
APP/PS1-treated animals were analyzed.
Double-labeling immunofluorescence
De-waxed sections were incubated with 98%
formic acid (3 min) for A immunofluorescence and
then treated with citrate buffer (20 min) to enhance
antigenicity. Sections were stained with a saturated
solution of Sudan black B for 10 min (Merck Mil-
lipore) to block lipofuscin autofluorescence, and
then rinsed in 70% ethanol and washed in dis-
tilled water. After a blockade with 10% fetal bovine
serum (90 min), the sections were incubated at 4ºC
overnight with combinations of primary antibodies
against A (clone 6F/3D 1:50, Dako), glial fib-
rillary acidic protein (GFAP; 1:250, Dako), IBA1
(1:250, Wako, Richmond, VA, USA) or phospho-Tau
(Thr181) (1:250, Merck Millipore). After wash-
ing, the sections were incubated with Alexa488 or
Alexa546 fluorescence secondary antibodies against
the corresponding host species (1:400, Molecular
Probes, Eugene, OR, USA). Then they were washed
and mounted in Immuno-Fluore Mounting medium
(ICN Biomedicals, Solon, OH, USA), sealed, dried
overnight, and examined with a Nikon Eclipse E800
microscope coupled to a camera (Jenoptik I Opti-
cal Systems, Germany) controlled from the ProgRes®
CapturePro 2.7 software (Jenoptik). For each animal,
the specific GFAP, IBA1 and phospho-Tau (Thr181)
immunostaining density was calculated in reference
to the A plaque area in 5 pictures taken from the
cingular/retrospenial and motor cortices, somatosen-
sory cortex or piriform/entorrhinal cortex using the
Adobe® Photoshop® CS4 software. No differences
were observed in the glial or tau phosphorylation
response depending on cortical region. The criteria
for choosing such plaques were (1) medium in size,
(2) with a condensed center and (3) not associated to
vascular processes or to other plaques.
Statistical analysis
The sample size for experimentation was com-
puted using the Power and Precision software
(Biostat, Englewood, NJ, USA), assuming a power
of 95% and no missing data. Statistical analysis was
performed with the SPSS® Statistics v21.0 software
(IBM, New York, NY, USA). The normality of the
data was assessed with the Shapiro-Wilk test and as
a consequence parametric statistical tests were used
for the analysis of all the data in the study. The fre-
quency of observed genotypes was analyzed with
Pearson’s chi-squared test (χ2) test. Memory perfor-
mance at different ages was analyzed with two-way
ANOVA with APP/PS1 transgene and CB2 muta-
tion as between factors, followed by Tukey’s post
hoc when required. Cognitive evaluation after chronic
treatment was analyzed with three-way ANOVA with
APP/PS1 transgene, CB2 mutation and treatment
as between factors, followed by Tukey’s post hoc
when required. A and glia or phosphorylated tau
quantifications were analyzed with two-way ANOVA
with CB2 mutation and treatment as between fac-
tors, followed by Tukey’s post hoc when required. In
all the experiments, the significance level was set at
p < 0.05.
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RESULTS
Viability and memory performance of AβPP/PS1
deficient for CB2 receptors
As shown in Fig. 1A, crossing APP/PS1/CB2
HET males with WT/CB2 HET females resulted
in the generation of pups bearing six different
genotypes. The Pearson’s chi-squared test (χ2) test
revealed that observed frequencies of each genotype
were not significantly different from the expected fre-
quencies according to Mendelian laws: 50% WT and
50% APP/PS1, and for each one of these genotypes
25% CB2 WT, 50% CB2 HET and 25% CB2 KO.
Thus, CB2 receptor deficiency does not compromise
the viability of APP/PS1 and WT mice. Moreover,
the mortality of CB2 mutant mice was not increased
in APP/PS1 and WT mice, at least up to six months
of age, when the chronic treatment started. None of
the genotypes exhibited physical abnormalities.
Fig. 1. A) Distribution of the genotypes in the offspring from mat-
ing of APP/PS1/CB2 heterozygous males (HET) and WT/CB2
HET females. The observed genotype frequencies were not sig-
nificantly different from the expected frequencies according to the
Mendelian laws. N, total number of mice studied. B) Memory per-
formance of animals aged 3 months (left; pre-symptomatic phase
in APP/PS1 mice) and 6 months (right; early symptomatic phase)
in the two-object recognition test. CB2 deletion does not acceler-
ate memory impairment in APP/PS1 mice. In contrast, WT/CB2
KO exhibit a tendency toward decrease in the recognition index
at 3 and 6 months with respect to WT/CB2 WT littermates. Data
are expressed as the mean values ± SEM. ∗∗p < 0.01 compared to
WT/CB2 WT mice.
In order to evaluate a potential acceleration
of the AD-related cognitive impairment in the
APP/PS1/CB2 KO mice, memory performance of
mutant mice was assessed at 3 (pre-symptomatic
phase in APP/PS1 mice) and 6 (early symptomatic
phase) months of age. No significant difference
between genotypes was observed at 3 months of age.
In contrast, two-way ANOVA revealed a significant
effect of the APP/PS1 transgene (F(1,34) = 8.644,
p < 0.01), no effect of CB2 deletion, but interac-
tion between the two genotypes (F(1,34) = 4.492,
p < 0.05) at 6 months of age. Subsequent post hoc
test revealed memory impairment in APP/PS1/CB2
WT mice when compared to WT/CB2 WT littermates
(p < 0.01). WT/CB2 KO mice exhibited a tendency
to reduce memory impairment at 3 and 6 months
although without statistical significance. This fact
contributed to the absence of significant memory
impairment in APP/PS1/CB2 KO mice when com-
pared to WT/CB2 KO littermates at 6 months, in
spite of the lower recognition index exhibited by
APP/PS1/CB2 KO mice (Fig. 1B). Therefore, it can
be concluded that CB2 deficiency does not accelerate
memory impairment in APP/PS1 mice.
CB2 receptor deficiency does not reduce the
cognitive improvement induced by natural
cannabinoids in AβPP/PS1 mice
Daily administration of 9-THC BDS and CBD
BDS (0.75 mg/kg each botanical extract i.p.) for 5
weeks at the early stages of the symptomatic phase
(6 months) blunted the memory impairment observed
in vehicle-treated APP/PS1 mice when compared to
WT animals as revealed by the two-object recogni-
tion test both in CB2 WT and CB2 KO mice (Fig. 2A).
Details of the three-way ANOVA are shown in Sup-
plementary Table 1. Subsequent Tukey’s post hoc
tests revealed memory impairment in vehicle-treated
APP/PS1/CB2 WT mice with respect to WT/CB2
WT mice (p < 0.001). In spite of the lower recognition
index exhibited by APP/PS1/CB2 KO treated with
vehicle, no significant difference was observed when
compared to WT/CB2 KO mice treated with vehi-
cle, likely due to the WT/CB2 KO tendency to show
reduced memory performance with respect WT/CB2
WT littermates. 9-THC + CBD BDS significantly
increased the recognition index of APP/PS1/CB2
WT (p < 0.01) and APP/PS1/CB2 KO (p < 0.01)
mice when compared to vehicle-treated littermates
bearing the same genotype.
494 E. Aso et al. / CB2 Role in Cannabis-Based Therapy for AD
Fig. 2. A) Memory performance of animals treated during the early symptomatic stage (6 months): APP/PS1/CB2 WT mice chronically
treated with vehicle exhibit significant reduction in the recognition index when compared to corresponding wild-type littermates. Similar
memory impairment is observed in vehicle-treated APP/PS1/CB2 KO mice although the reduction in the recognition index with respect to
WT/CB2 KO does not reach statistical significance. Chronic 9-THC + CBD BDS (0.75 mg/kg each, i.p.) administration induces memory
improvement in APP/PS1 independently of the presence or absence of CB2 receptor when compared to corresponding control group. B, C)
The number of conditioned changes in the active avoidance test is recorded during 5 consecutive days to evaluate learning performance. B)
No significant differences in the number of conditioned changes during the 5 days are observed in any of the groups of mice not bearing the
APP/PS1 transgene. C) Vehicle-treated APP/PS1/CB2 WT exhibit a significant reduction in learning performance compared to WT/CB2
WT on day 5. The number of conditioned changes achieved by vehicle-treated APP/PS1/CB2 KO is reduced on days 2, 3, and 5 with
respect to WT/CB2 KO. In contrast, APP/PS1 mice chronically treated with the combination of 9-THC + CBD BDS did not evidence such
learning impairment at any time point independently of the presence or absence of CB2 receptor. A significant treatment effect is observed
in APP/PS1/CB2 KO mice on days 2 and 5. Data are expressed as the mean values ± SEM. ∗p < 0.05, ∗∗∗p < 0.001 compared to animals
not bearing the APP/PS1 transgene; #p < 0.05, ##p < 0.01 compared to vehicle-treated littermates.
Learning performance was evaluated with the
active avoidance test in order to assess the effects of
the natural cannabinoids on a more complex cognitive
task. Details of the three-way ANOVA are shown in
Supplementary Table 1; comparisons between groups
were assessed with Tukey’s post hoc test when inter-
action between factors was significant. In the active
avoidance test, WT/CB2 KO mice did not exhibit any
tendency to reduce their cognitive performance with
respect WT/CB2 WT littermates as occurred in the
two object recognition task. The number of achieved
conditioned changes was reduced in vehicle-treated
APP/PS1/CB2 WT mice on day 5 (p < 0.05), and
in vehicle-treated APP/PS1/CB2 KO mice on day
2 (p < 0.05), day 3 (p < 0.05), and day 5 (p < 0.05)
when compared with vehicle-treated WT/CB2 WT
and WT/CB2 KO animals, respectively (Fig. 2B, C).
In contrast, APP/PS1/CB2 WT and APP/PS1/CB2
KO mice chronically treated with the combination of
9-THC + CBD BDS did not show learning impair-
ment at any time when compared to the corresponding
treated WT controls (Fig. 2B, C). Moreover, a signif-
icant improvement was observed in APP/PS1/CB2
KO mice chronically treated with 9-THC + CBD
BDS on day 2 (p < 0.05) and day 5 (p < 0.05) when
compared to vehicle-treated APP/PS1/CB2 KO lit-
termates. These results demonstrate that 9-THC +
CBD BDS rescued APP/PS1 learning impairment
in the active avoidance paradigm when administered
at the beginning of the symptomatic stage in CB2
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Fig. 3. A) Total A burden quantification in cortical sections reveals increased A deposition in APP/PS1/CB2 KO mice (black bars)
compared to APP/PS1/CB2 WT littermates (open bars) at the end of the treatment period, but no significant effect induced by the 9-THC
+ CBD BDS in any of the APP/PS1 groups. B) Low magnification images showing representative brain sections stained with a specific
antibody against total A. Scale bar represents 1000 m. C) 9-THC + CBD BDS significantly increases the percentage of A42 in plaques,
calculated as the contents of A42 with respect to the total A40 + A42 deposition, in both APP/PS1/CB2 WT and APP/PS1/CB2 KO
mice. D) Representative images of A40 and A42 specific immunoreactivity in consecutive cortical sections of APP/PS1/CB2 WT (upper)
and APP/PS1/CB2 KO (bottom) mice chronically treated with vehicle (left) or with 9-THC + CBD BDS (right). Scale bar represents
200 m. E) Increased soluble A40 levels in cortical homogenates from APP/PS1 mice deficient for CB2 receptor; 9-THC + CBD BDS
does not modify A40 levels in APP/PS1/CB2 WT and APP/PS1/CB2 KO mice evaluated with ELISA. F) No significant effect of genotype
or treatment is observed in cortical soluble A42 levels in spite of a tendency toward A42 protein level reduction in APP/PS1/CB2 WT
when compared to vehicle-treated controls. Counts expressed as mean values ± SEM. ∗p < 0.05, ∗∗p < 0.01 compared to APP/PS1/CB2
WT.
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Fig. 4. A) Representative images of double GFAP (red, upper panels) and IBA1 (red, lower panels) and A (green) immunoreactivity
in cortical sections of APP/PS1 mice chronically treated during the early symptomatic phase with natural cannabinoids. Scale bar rep-
resents 100 m. B) Quantification of GFAP staining around A plaques reveals a significant reduction in the astroglial response in both
APP/PS1/CB2 WT and APP/PS1/CB2 KO mice chronically treated with 9-THC + CBD BDS. C) Quantification of IBA1 staining around
A plaques reveals a tendency toward microglial cell reduction in APP/PS1/CB2 KO and a significant reduction in microglial response in
9-THC + CBD BDS-treated APP/PS1/CB2 WT, but not in APP/PS1/CB2 KO mice, when compared to corresponding vehicle control
groups. Data are expressed as the mean values ± SEM. #p < 0.05, ##p < 0.01 compared to vehicle-treated littermates.
functional and CB2 KO backgrounds. Together, these
results suggest that CB2 receptors do not play a rel-
evant role in the cognitive improvement induced by
natural cannabinoids in APP/PS1 mice.
Deficiency in CB2 receptors alters Aβ processing
but not the Δ9-THC + CBD BDS effect on Aβ
plaque composition in AβPP/PS1 mice
At 3 months of age, no significant difference
was observed between the cortical A burden in
APP/PS1/CB2 WT (%Area with A plaques:
0.06 ± 0.01) and APP/PS1/CB2 KO mice (%Area
with A plaques: 0.05 ± 0.01). No A plaques were
observed in hippocampus of APP/PS1 mice at 3
months of age. However, APP/PS1/CB2 KO mice
exhibited an increase in the total A deposition
with respect to APP/PS1/CB2 WT littermates at the
end of the chronic treatment period (≈ 8 months
of age), independently of the treatment received
(Fig. 3A, B). Two-way ANOVA revealed a significant
genotype effect (Cortex: F(1,32) = 6.418, p < 0.05;
Hippocampus: F(1,29) = 5.030, p < 0.05), but no treat-
ment effect and no interaction between the two
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Fig. 5. A) Representative images of double phospho-tau (Thr181) (red) and A (green) immunoreactivity in cortical sections of
APP/PS1/CB2 WT (upper panels) and APP/PS1/CB2 KO (lower panels) mice chronically treated with vehicle (left) or 9-THC +
CBD BDS (right). Scale bar represents 50 m. B) Quantification of phospho-tau (Thr181) staining in the vicinity of A plaques reveals
no significant effect of CB2 receptor genotype or treatment on tau phosphorylation in APP/PS1 mice. Data are expressed as the mean
values ± SEM.
factors. As expected, A burden was more relevant
in cortex than hippocampus in APP/PS1 mice. The
deficiency in CB2 receptors did not alter the compo-
sition of plaques and did not reduce the increase in
the A42/A40 ratio in plaques induced by 9-THC
+ CBD BDS both in APP/PS1/CB2 WT (p < 0.05)
and APP/PS1/CB2 KO (p < 0.01) mice (Fig. 3C,
D), as revealed with the two-way ANOVA (Treat-
ment effect: F(1,15) = 18.130, p < 0.001; Genotype
effect and interaction: not significant) and subse-
quent post hoc tests. An increase in the soluble
levels of A40, but not A42, was observed in the
cortex of APP/PS1/CB2 KO mice treated with
vehicle (p < 0.05) and with 9-THC + CBD BDS
(p < 0.01) as revealed with two-way ANOVA (Geno-
type effect: F(1,25) = 14.390, p < 0.001; Treatment
effect and interaction: not significant) and subsequent
post hoc tests (Fig. 3E, F).
CB2 receptor plays a role in the microglial
response to Aβ deposition induced by natural
cannabinoids in AβPP/PS1 mice
Astrocytic and microglial responses to A plaques
were evaluated with double-labeling immunofluo-
rescence and densitometric quantification. Two-way
ANOVA revealed a treatment effect (F(1,15) = 3.548,
p < 0.001) but no genotype effect or interaction
between the two factors in the astroglial response.
Subsequent post hoc tests indicated that the com-
bination of 9-THC + CBD BDS reduced the
astrocytic reactivity in both APP/PS1/CB2 WT
(p < 0.01) and APP/PS1/CB2 KO mice (p < 0.05)
when compared to corresponding vehicle-treated
controls (Fig. 4A, B). Regarding microglial reactiv-
ity, two-way ANOVA revealed a significant effect
of treatment (F(1,16) = 8.104, p < 0.05), but no geno-
type effect and no interaction between the two
factors (F(1,16) = 5.550, p < 0.05). Subsequent post
hoc tests indicated that the number of microglial
cells associated with A plaques was significantly
reduced by 9-THC + CBD BDS in APP/PS1/CB2
WT (p < 0.05), but not in APP/PS1/CB2 KO mice
when compared to the corresponding vehicle-treated
group (Fig. 4A, C). A tendency without statisti-
cal significance to reduce numbers of microglial
cells around A plaques was observed in vehicle-
treated APP/PS1/CB2 KO mice when compared to
APP/PS1/CB2 WT littermates.
Tau phosphorylation in the vicinity of Aβ plaques
is not modified by CB2 receptor deficiency or
natural cannabinoids treatment in AβPP/PS1 mice
APP/PS1 mice do not produce neurofibrillary
tangles at any age but they present small amounts of
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hyperphosphorylated tau in dystrophic neurites sur-
rounding A plaques, which are suggested to be a
consequence of the detrimental effect of soluble A
in neurons and to contribute to the neurodegenerative
process [35]. For these reasons, we decided to eval-
uate the levels of tau phosphorylated at Thr181, the
most abundantly phosphorylated site in our animal
model of AD, by double-immunofluorescence and
quantitative densitometry. No significant differences
related to CB2 receptor deficiency and/or treatment
were observed in the levels of tau phosphorylated
at the Thr181 site in the vicinity of A plaques in
APP/PS1 mice (Fig. 5A, B).
DISCUSSION
APP/PS1 transgenic mice lacking the CB2 recep-
tor generated in the present study revealed that this
cannabinoid receptor plays a minor role in the thera-
peutic effects of the combination of 9-THC + CBD
BDS natural cannabinoids but demonstrated a link
between CB2 receptor and AD progression.
CB2 receptor deficiency does not compromise the
viability of APP/PS1 and WT mice at least up
to 6 months of age. Lack of CB2 receptor induces
a tendency to memory impairment in WT mice in
the two object recognition test, according to pre-
vious reports [36], although does not accelerate
the memory impairment in APP/PS1 mice. How-
ever, APP/PS1/CB2 KO mice exhibit increased A
deposits (cerebral cortex and hippocampus) and cor-
tical A40 soluble levels at 6 (early symptomatic
phase), but not at 3 (pre-symptomatic phase) months
of age. Similar observations have been described in
another AD model bearing CB2 receptor deletion
[22]. These findings suggest a role for CB2 recep-
tor in A clearance rather than in the production of
this peptide. This hypothesis is also supported by
previous studies showing that CB2 receptor pharma-
cological activation facilitates A transport through
the choroid plexus [16] and A removal by immune
cells [15, 17]. The present results together with recent
reports [37] also indicate that CB2 receptor dele-
tion in APP/PS1 mice results in a reduction of
the microglial, but not astroglial, response to A
deposition. Thus, altered microglial responses in AD
models lacking CB2 receptor are accompanied by
modification of the levels of molecules involved in
neuroinflammation [22, 37]. Moreover, we have also
evaluated the levels of hyperphosphorylated tau pro-
tein in the A plaques surrounding area because,
although APP/PS1 mice present only small amounts
of hyperphosphorylated tau that are never on a par
with those seen in AD brains, they are supposed
to reflect a detrimental effect of soluble A and
to contribute to the neurodegenerative process [35].
Additional interest on the study of tau phospho-
rylation in APP/PS1 mice lacking CB2 receptors
derived from previous evidence showing a specific
role for these cannabinoid receptors in tau phos-
phorylation by using pharmacological and genetic
models [21, 22]. Nevertheless, APP/PS1/CB2 KO
mice exhibit similar levels of hyperphosphorylated
tau in the dystrophic neurites associated to A
plaques than CB2 receptors sufficient APP/PS1
mice, suggesting that these cannabinoid receptors
do not play a crucial role in tau phosphorylation in
our animal model of AD. These findings collectively
demonstrate a role for CB2 receptors in the patho-
logical progression of AD primarily related to A
processing.
The administration of 9-THC + CBD BDS, con-
taining mainly 9-THC with a mixed action on CB1
and CB2 receptors and CBD with activity on other
receptors [30], at a therapeutic dose in APP/PS1
mice [23] is as effective in APP/PS1/CB2 KO mice
as in APP/PS1 mice not lacking CB2 receptors.
Thus, the combination of the two natural cannabis
extracts reduces memory and learning impairment,
increases A42 contents in plaques, and decreases the
astroglial reactivity to A deposition in APP/PS1
mice as previously described [23] independently
of the presence or absence of CB2 receptors. In
contrast, 9-THC + CBD BDS administration has
no effect on the microglial reactivity or tau phos-
phorylation around A plaques in APP/PS1/CB2
KO mice. These results suggest that other mecha-
nisms apart from CB2 receptor signaling are involved
in the positive effects of these natural cannabi-
noids in APP/PS1 mice. Some potential targets
involved in such effects might be CB1, GPR55 or
other G-coupled receptors for which 9-THC or
CBD compounds exhibited certain activity. However,
further research is needed to unravel the specific con-
tribution of such receptors on the beneficial effect
produced by the natural cannabinoids on the AD
model.
In conclusion, the contribution of CB2 receptors
to the therapeutic properties of the cannabis-based
medicine composed mainly of 9-THC and CBD
is minor although CB2 receptors participate in the
progression of the AD pathology in our animal
model.
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de Yébenes JG, Mena MA (2013) Natural cannabinoids
improve dopamine neurotransmission and tau and amyloid
pathology in a mouse model of tauopathy. J Alzheimers Dis
35, 525-539.
[25] Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K,
Nabar N, Cai J (2014) The potential therapeutic effects
500 E. Aso et al. / CB2 Role in Cannabis-Based Therapy for AD
of THC on Alzheimer’s disease. J Alzheimers Dis 42,
973-984.
[26] Martı́n-Moreno AM, Reigada D, Ramı́rez BG, Mechoulam
R, Innamorato N, Cuadrado A, de Ceballos ML (2011)
Cannabidiol and other cannabinoids reduce microglial acti-
vation in vitro and in vivo: Relevance to Alzheimer’s disease.
Mol Pharmacol 79, 964-973.
[27] Cheng D, Low JK, Logge W, Garner B, Karl T (2014)
Chronic cannabidiol treatment improves social and object
recognition in double transgenic APPswe/PS1E9 mice.
Psychopharmacology (Berl) 231, 3009-3017.
[28] Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014)
Long-term cannabidiol treatment prevents the development
of social recognition memory deficits in Alzheimer’s disease
transgenic mice. J Alzheimers Dis 42, 1383-1396.
[29] Huestis MA (2005) Pharmacokinetics and metabolism
of the plant cannabinoids, delta9-tetrahydrocannabinol,
cannabidiol and cannabinol. Handb Exp Pharmacol 168,
657-690.
[30] Pertwee RG (2008) The diverse CB1 and CB2 recep-
tor pharmacology of three plant cannabinoids: Delta9-
tetrahydrocannabinol, cannabidiol and delta9-tetrahydro-
cannabivarin. Br J Pharmacol 153, 199-215.
[31] Russo EB (2011) Taming THC: Potential cannabis syn-
ergy and phytocannabinoid-terpenoid entourage effects. Br
J Pharmacol 163, 1344-1364.
[32] Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales
V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997)
Accelerated amyloid deposition in the brains of transgenic
mice coexpressing mutant presenilin 1 and amyloid precur-
sor proteins. Neuron 19, 939-945.
[33] Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A,
Felder CC, Glass M, Zimmer A (2000) Immunomodulation
by cannabinoids is absent in mice deficient for the cannabi-
noid CB(2) receptor. Eur J Pharmacol 396, 141-149.
[34] Aso E, Palomer E, Juvés S, Maldonado R, Muñoz FJ, Ferrer
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